Cargando…
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to pro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402814/ https://www.ncbi.nlm.nih.gov/pubmed/34452509 http://dx.doi.org/10.3390/v13081645 |
_version_ | 1783745881522044928 |
---|---|
author | van Doremalen, Neeltje Fischer, Robert J. Schulz, Jonathan E. Holbrook, Myndi G. Smith, Brian J. Lovaglio, Jamie Petsch, Benjamin Munster, Vincent J. |
author_facet | van Doremalen, Neeltje Fischer, Robert J. Schulz, Jonathan E. Holbrook, Myndi G. Smith, Brian J. Lovaglio, Jamie Petsch, Benjamin Munster, Vincent J. |
author_sort | van Doremalen, Neeltje |
collection | PubMed |
description | Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates. |
format | Online Article Text |
id | pubmed-8402814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84028142021-08-29 Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates van Doremalen, Neeltje Fischer, Robert J. Schulz, Jonathan E. Holbrook, Myndi G. Smith, Brian J. Lovaglio, Jamie Petsch, Benjamin Munster, Vincent J. Viruses Article Many different vaccine candidates against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, are currently approved and under development. Vaccine platforms vary from mRNA vaccines to viral-vectored vaccines, and several candidates have been shown to produce humoral and cellular responses in small animal models, non-human primates, and human volunteers. In this study, six non-human primates received a prime-boost intramuscular vaccination with 4 µg of mRNA vaccine candidate CV07050101, which encodes a pre-fusion stabilized spike (S) protein of SARS-CoV-2. Boost vaccination was performed 28 days post prime vaccination. As a control, six animals were similarly injected with PBS. Humoral and cellular immune responses were investigated at time of vaccination, and two weeks afterwards. No antibodies could be detected at two and four weeks after prime vaccination. Two weeks after boost vaccination, binding but no neutralizing antibodies were detected in four out of six non-human primates. SARS-CoV-2 S protein-specific T cell responses were detected in these four animals. In conclusion, prime-boost vaccination with 4 µg of vaccine candidate CV07050101 resulted in limited immune responses in four out of six non-human primates. MDPI 2021-08-19 /pmc/articles/PMC8402814/ /pubmed/34452509 http://dx.doi.org/10.3390/v13081645 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article van Doremalen, Neeltje Fischer, Robert J. Schulz, Jonathan E. Holbrook, Myndi G. Smith, Brian J. Lovaglio, Jamie Petsch, Benjamin Munster, Vincent J. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates |
title | Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates |
title_full | Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates |
title_fullStr | Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates |
title_full_unstemmed | Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates |
title_short | Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates |
title_sort | immunogenicity of low-dose prime-boost vaccination of mrna vaccine cv07050101 in non-human primates |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402814/ https://www.ncbi.nlm.nih.gov/pubmed/34452509 http://dx.doi.org/10.3390/v13081645 |
work_keys_str_mv | AT vandoremalenneeltje immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT fischerrobertj immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT schulzjonathane immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT holbrookmyndig immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT smithbrianj immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT lovagliojamie immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT petschbenjamin immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates AT munstervincentj immunogenicityoflowdoseprimeboostvaccinationofmrnavaccinecv07050101innonhumanprimates |